Stryker Co. (NYSE:SYK) Shares Purchased by Lokken Investment Group LLC

Lokken Investment Group LLC raised its stake in Stryker Co. (NYSE:SYK) by 2.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,796 shares of the medical technology company’s stock after acquiring an additional 83 shares during the quarter. Lokken Investment Group LLC’s holdings in Stryker were worth $1,367,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of SYK. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Stryker in the 4th quarter valued at $25,000. Dunhill Financial LLC increased its holdings in Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares in the last quarter. Rakuten Securities Inc. raised its position in shares of Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after acquiring an additional 68 shares during the period. Centricity Wealth Management LLC acquired a new stake in shares of Stryker during the 4th quarter valued at about $30,000. Finally, BankPlus Trust Department purchased a new position in shares of Stryker in the 4th quarter valued at about $33,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other news, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Stryker Stock Up 2.3 %

Shares of NYSE:SYK opened at $372.73 on Tuesday. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The stock has a market cap of $142.27 billion, a P/E ratio of 48.03, a PEG ratio of 2.93 and a beta of 0.95. The business has a fifty day moving average of $383.86 and a two-hundred day moving average of $374.41. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company earned $3.46 earnings per share. On average, research analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is presently 43.30%.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of recent analyst reports. Citigroup reiterated a “buy” rating and set a $450.00 price target on shares of Stryker in a research report on Wednesday, February 26th. Truist Financial lifted their price target on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research note on Thursday, January 30th. Royal Bank of Canada upped their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. Wells Fargo & Company increased their price objective on shares of Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.